Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.17%
- Poor long term growth as Net Sales has grown by an annual rate of -8.65% and Operating profit at -187.97% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
The company has declared Negative results for the last 4 consecutive quarters
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,724 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.61
-12.10%
2.17
Revenue and Profits:
Net Sales:
277 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
46.16%
0%
46.16%
6 Months
51.2%
0%
51.2%
1 Year
24.53%
0%
24.53%
2 Years
40.08%
0%
40.08%
3 Years
4.55%
0%
4.55%
4 Years
-17.97%
0%
-17.97%
5 Years
-1.3%
0%
-1.3%
Jiangxi Fushine Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.65%
EBIT Growth (5y)
-187.97%
EBIT to Interest (avg)
1.19
Debt to EBITDA (avg)
25.53
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.32
Tax Ratio
2.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.17%
ROE (avg)
2.55%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.17
EV to EBIT
-23.04
EV to EBITDA
-71.21
EV to Capital Employed
1.73
EV to Sales
6.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-7.50%
ROE (Latest)
-12.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
276.70
229.70
20.46%
Operating Profit (PBDIT) excl Other Income
44.00
34.00
29.41%
Interest
9.80
10.40
-5.77%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.60
0.60
-1,866.67%
Operating Profit Margin (Excl OI)
-9.60%
-54.90%
4.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 20.46% vs 16.66% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -1,866.67% vs 100.28% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,161.20
1,593.00
-27.11%
Operating Profit (PBDIT) excl Other Income
-22.00
-16.30
-34.97%
Interest
41.50
43.10
-3.71%
Exceptional Items
-101.90
-24.20
-321.07%
Consolidate Net Profit
-280.50
-223.30
-25.62%
Operating Profit Margin (Excl OI)
-164.50%
-109.00%
-5.55%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -27.11% vs -2.39% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -25.62% vs -35.99% in Dec 2023
About Jiangxi Fushine Pharmaceutical Co., Ltd. 
Jiangxi Fushine Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






